Aug 12 (Reuters) - PolarityTE Inc PTE.O :
* POLARITYTE REPORTS SECOND QUARTER FINANCIAL RESULTS AND
PROVIDES
BUSINESS UPDATE
* Q2 REVENUE $2.54 MILLION
* Q2 REVENUE ESTIMATE $3.2 MILLION -- REFINITIV IBES DATA
* REPORTED SKINTE MET PRIMARY AND SECONDARY ENDPOINTS IN
FINAL
ANALYSIS FROM DIABETIC FOOT ULCER (DFU) TRIAL
* CEASED COMMERCIAL SALES OF SKINTE ON MAY 31, AND HAS MADE
SUBSTANTIAL REDUCTIONS IN COSTS ASSOCIATED WITH ITS COMMERCIAL
OPERATIONS
* ON JULY 23, 2021 COMPANY SUBMITTED TO FDA AN IND FOR
SKINTE FOR
TREATMENT OF CHRONIC CUTANEOUS ULCERS.
* QTRLY LOSS PER SHARE $0.06
Source text for Eikon: ID:nBw9DSh12a
Further company coverage: PTE.O
((Reuters.Briefs@thomsonreuters.com;))